The feasibility of HIV vaccine efficacy trials among Russian injection drug users

Chris Beyrer, Stefan Baral, Alla Shaboltas, Elena Dukhovlinova, Alexey Masharsky, Sergey Verevochkin, Carl Latkin, Robert Heimer, Irving Hoffman, Andrei Kozlov

Research output: Contribution to journalArticle

Abstract

IDU exposure remains a primary driver of the Russian HIV epidemic, and recent incidence data provide little evidence that this epidemic is slowing. While there are multiple important challenges that need to be further explored before starting vaccine trials, most importantly access to evidence-based drug treatment services for trial participants, the current context of high HIV incidence and low genetic diversity of HIV strains, suggests the need for intensified prevention strategies and supports the feasibility of mounting efficacy trials of HIV vaccines among IDUs in the Russian Federation.

Original languageEnglish (US)
Pages (from-to)7014-7016
Number of pages3
JournalVaccine
Volume25
Issue number41
DOIs
StatePublished - Oct 10 2007

    Fingerprint

Keywords

  • HIV
  • Injection drug use
  • Molecular epidemiology
  • St. Petersburg
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Beyrer, C., Baral, S., Shaboltas, A., Dukhovlinova, E., Masharsky, A., Verevochkin, S., Latkin, C., Heimer, R., Hoffman, I., & Kozlov, A. (2007). The feasibility of HIV vaccine efficacy trials among Russian injection drug users. Vaccine, 25(41), 7014-7016. https://doi.org/10.1016/j.vaccine.2007.07.028